Amneal Pharmaceuticals, Inc.
AMRX
$12.60
-$0.18-1.41%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 122.12M | 72.06M | 5.90M | 3.38M | -13.05M |
| Total Depreciation and Amortization | 206.60M | 223.57M | 240.48M | 245.36M | 240.82M |
| Total Amortization of Deferred Charges | 19.51M | 22.43M | 25.53M | 28.53M | 29.11M |
| Total Other Non-Cash Items | 245.83M | 226.45M | 226.22M | 150.68M | 148.51M |
| Change in Net Operating Assets | -288.22M | -204.52M | -170.37M | -76.87M | -98.47M |
| Cash from Operations | 305.84M | 339.99M | 327.76M | 351.08M | 306.92M |
| Capital Expenditure | -98.58M | -98.84M | -78.14M | -80.20M | -64.40M |
| Sale of Property, Plant, and Equipment | 1.57M | 2.09M | 1.38M | 1.38M | 524.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | 7.01M | 7.01M | 11.99M |
| Other Investing Activities | -19.16M | -15.51M | -13.11M | -9.30M | -9.15M |
| Cash from Investing | -116.18M | -112.26M | -82.87M | -81.12M | -61.03M |
| Total Debt Issued | 2.84B | 2.92B | 2.92B | 218.00M | 218.00M |
| Total Debt Repaid | -2.72B | -2.81B | -2.86B | -393.82M | -405.27M |
| Issuance of Common Stock | 1.93M | 1.96M | 1.56M | 1.52M | 1.20M |
| Repurchase of Common Stock | -44.94M | -22.28M | -22.34M | -22.41M | -22.38M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -127.88M | -118.82M | -119.23M | -37.70M | -19.35M |
| Cash from Financing | -51.42M | -31.53M | -82.61M | -234.40M | -227.80M |
| Foreign Exchange rate Adjustments | -2.23M | -1.68M | -2.21M | -1.51M | -1.30M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 136.01M | 194.52M | 160.06M | 34.05M | 16.78M |